Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brightline-1 brigimadlin versus doxorubicin in first-line advanced dedifferentiated liposarcoma
NL-OMON53837Phase 2Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of brigimadlin in dedifferentiated liposarcoma (DDL) (5 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Progression-free survival. Started Aug 2022; status: recruiting.
02
Drugs
brigimadlin
03
Conditions
dedifferentiated liposarcoma (DDL)
Beyond the preview
Go deeper on NL-OMON53837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53837.